STOCK TITAN

Amesite (NASDAQ: AMST) adds at-the-market stock offering with H.C. Wainwright

(Moderate)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Amesite Inc. entered into an At The Market Offering Agreement on July 17, 2026 with H.C. Wainwright & Co., LLC as sales agent, allowing Amesite to offer and sell shares of its common stock from time to time, up to a maximum aggregate offering price defined as the “Maximum Amount” in the agreement. Sales will be made as at-the-market offerings on The Nasdaq Capital Market or by other permitted methods at market prices or as otherwise agreed with the agent, under an effective Form S-3 shelf registration statement and related prospectus supplement.

H.C. Wainwright will use commercially reasonable efforts to execute sales based on Amesite’s instructions, and Amesite is not obligated to sell any shares, nor is the agent obligated to purchase shares on a principal basis. Amesite will pay a 3.0% commission on aggregate gross proceeds from each sale and reimburse specified expenses, including up to $50,000 of the agent’s legal fees and costs. Net proceeds, if any, are intended for general corporate and working capital purposes, with management retaining broad discretion over their allocation. The at-the-market program will end when all shares covered by the agreement are sold or the agreement is terminated under its terms.

Positive

  • None.

Negative

  • None.
Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Sales commission 3.0% of aggregate gross proceeds Commission rate payable to H.C. Wainwright on each sale of Shares
Expense reimbursement cap $50,000 Maximum aggregate reimbursement for the agent’s legal counsel fees entering the ATM Agreement
Common stock par value $0.0001 per share Par value of Amesite’s common stock offered under the at-the-market program
At The Market Offering Agreement financial
"entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright"
An at-the-market offering agreement is a contract that lets a company sell newly issued shares directly into the open market through a broker, at whatever price the stock is trading at that moment. For investors this matters because it can increase the number of shares available (which may dilute existing ownership) while providing a flexible, often faster way for the company to raise cash without fixing a price, similar to a vendor selling small batches at current market stalls rather than setting a single fixed price.
shelf registration statement regulatory
"pursuant to a shelf registration statement on Form S-3 and the related prospectus"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
prospectus supplement regulatory
"and prospectus supplement related to the offering of Shares filed with the SEC"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
General Instruction I.B.6 regulatory
"permitted to be sold under Form S-3 (including General Instruction I.B.6 thereof, if applicable)"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What agreement did Amesite (AMST) enter into on July 17, 2026?

Amesite entered an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, enabling sales of its common stock under an effective Form S-3 shelf registration and related prospectus supplement, up to a contractually defined Maximum Amount.

How will Amesite (AMST) shares be sold under the at-the-market program?

Shares may be sold in at-the-market offerings through H.C. Wainwright, including ordinary brokers’ transactions on The Nasdaq Capital Market at prevailing market prices or on other permitted terms, based on Amesite’s instructions on price, size, and timing.

What fees will Amesite (AMST) pay H.C. Wainwright under the ATM Agreement?

Amesite will pay a 3.0% commission on the aggregate gross proceeds from each stock sale and will reimburse specified expenses, including documented legal fees of the agent’s counsel up to $50,000, plus periodic due diligence and incidental expenses.

Is Amesite (AMST) required to sell shares under the At The Market Offering Agreement?

Amesite is not obligated to sell any shares under the agreement, and H.C. Wainwright is not obligated to purchase shares on a principal basis. Sales occur only when Amesite instructs the agent and applicable conditions in the agreement are satisfied.

How does Amesite (AMST) plan to use net proceeds from any ATM share sales?

Amesite currently intends to use any net proceeds from sales of shares for general corporate and working capital purposes. The amounts and timing of expenditures may vary, and management retains broad discretion over how the proceeds are ultimately allocated.

When will Amesite’s (AMST) at-the-market offering program terminate?

The program will terminate upon the earlier of (i) the issuance and sale of all shares of common stock subject to the agreement or (ii) termination of the sales agreement in accordance with its terms, ending Amesite’s ability to sell shares under this specific arrangement.
false 0001807166 0001807166 2026-07-17 2026-07-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 17, 2026

 

Amesite Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-39553   82-3431718

(State or other jurisdiction

of incorporation)

  (Commission File Number)  

(IRS Employer

Identification No.)

 

607 Shelby Street

Suite 700 PMB 214

Detroit, MI

  48226
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (734) 876-8141

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   AMST   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

On July 17, 2026, Amesite Inc. (the “Company”), entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC as agent (the “Agent”), pursuant to which the Company may offer and sell, from time to time through the Agent, shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to the Maximum Amount (as defined in the ATM Agreement).

 

The offer and sale of the Shares will be made pursuant to a shelf registration statement on Form S-3 and the related prospectus (File No. 333-282999) (the “Registration Statement”) filed by the Company with the Securities and Exchange Commission (the “SEC”) on November 5, 2024, as amended and declared effective by the SEC on December 18, 2024, under the Securities Act of 1933, as amended (the “Securities Act”), and prospectus supplement related to the offering of Shares filed with the SEC on July 17, 2026.

 

Pursuant to the ATM Agreement, the Agent may sell the Shares by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 of the Securities Act, including sales made by means of ordinary brokers’ transactions, including on The Nasdaq Capital Market, at market prices or as otherwise agreed with the Agent. The Agent will use commercially reasonable efforts consistent with its normal trading and sales practices to sell the Shares from time to time, based upon instructions from the Company, including any price or size limits or other customary parameters or conditions the Company may impose.

 

Under the terms of the ATM Agreement, in no event will the Company issue or sell through the Agent such number or dollar amount of shares of Common Stock that would (i) exceed the number or dollar amount of shares of Common Stock registered and available on the Registration Statement, (ii) exceed the number of authorized but unissued shares of Common Stock, or (iii) exceed the number or dollar amount of shares of Common Stock permitted to be sold under Form S-3 (including General Instruction I.B.6 thereof, if applicable).

 

The Company is not obligated to make any sales of the Shares under the ATM Agreement, and the Agent is not obligated to purchase any Shares on a principal basis pursuant to the ATM Agreement, except as otherwise specifically agreed by the Agent and the Company in a separate agreement. No assurance can be given that the Company will sell any Shares under the ATM Agreement, or if such sales occur, no assurance can be given as to the price or number of Shares that will be sold, or the dates on which any such sales will take place. The offering pursuant to the ATM Agreement will terminate upon the earlier of (i) the issuance and sale of all shares of our common stock subject to the sales agreement, or (ii) the termination of the sales agreement as permitted therein.

 

The Company will pay the Agent a commission rate equal to 3.0% of the aggregate gross proceeds from each sale of Shares and has agreed to provide the Agent with customary indemnification and contribution rights. The Company will also reimburse the Agent for certain specified expenses in connection with entering into the ATM Agreement, including for the documented fees and costs of its legal counsel reasonably incurred in connection with entering into the transactions contemplated by the ATM Agreement in an amount not to exceed $50,000 in the aggregate, in addition to periodic due diligence fees, plus any incidental expense incurred by the Agent in connection therewith. The ATM Agreement contains customary representations and warranties and conditions to the sale of the Shares pursuant thereto.

 

1

 

 

We currently intend to use the net proceeds from the sale of Shares, if any, for general corporate and working capital purposes, however the amounts and timing of our actual expenditures may vary significantly depending on numerous factors, and as a result, our management will retain broad discretion over the allocation of the net proceeds from the sale of Shares.

 

The foregoing description of the ATM Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed herewith as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference. The opinion of Sheppard, Mullin, Richter & Hampton LLP, the Company’s counsel, regarding the validity of the Shares that will be issued pursuant to the Sales Agreement, is also filed herewith as Exhibit 5.1.

 

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Common Stock discussed herein, nor shall there be any offer, solicitation, or sale of common stock in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
5.1   Opinion of Sheppard, Mullin, Richter & Hampton LLP
10.1   At The Market Offering Agreement dated July 17, 2026 between Amesite Inc. and H.C. Wainwright & Co., LLC
23.1   Consent of Sheppard, Mullin, Richter & Hampton LLP (included in Exhibit 5.1)
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AMESITE INC.
     
Date: July 20, 2026 By: /s/ Ann Marie Sastry, Ph.D.
  Name:  Ann Marie Sastry, Ph.D.
  Title: Chief Executive Officer

 

3

 

Filing Exhibits & Attachments

5 documents